TABLE 1

Baseline group characteristics

Healthy controlCTEPHCTEDIPAHPE
Subjects n68208353028
Age years49 (24)64 (19)58 (27)64 (27)52 (26)
Female sex32 (47%)90 (43%)9 (26%)21 (70%)15 (54%)
Caucasian ethnicity53 (78%)180 (95%)28 (88%)26 (90%)13 (54%)
WHO functional class
 14 (2%)6 (18%)5 (17%)
 242 (21%)17 (50%)4 (13%)
 3151 (74%)11 (32%)21 (70%)
 47 (3%)0 (0%)0 (0%)
6MWD m318 (176)366 (180)342 (244)
Pulmonary haemodynamics
 mPAP mmHg42 (18)21 (4)42 (17)
 Cardiac index L·min−1·m−22 (0.6)2.4 (0.6)1.7 (0.8)
 PVR dynes·s·cm−5639 (476)151 (71)808 (642)
Clinical blood tests
 Haemoglobin g·L−1140 (27)138 (16)142 (22)
 Platelet count ×109246 (82)200 (56)222 (77)
 WCC ×1097 (3)6.6 (2.1)6.9 (2.4)
 Lymphocyte %25 (10)28 (13)18 (13)
 Neutrophil %64 (14)59 (14)72 (14)
 CRP mg·L−15 (10)3 (3)3 (4)
 NT-proBNP pg·mL−1592 (1576)113 (194)334 (695)
Smoking status
 Never91 (47%)16 (50%)15 (52%)
 Ex-smoker87 (45%)13 (41%)11 (38%)
 Current smoker15 (8%)3 (9%)3 (10%)
Anticoagulation medication137 (94%)15 (94%)30 (100%)

Data are presented as median (interquartile range) or n (%). Percentages were calculated using the number of patients for whom data were available as the denominator. CTEPH: chronic thromboembolic pulmonary hypertension; CTED: chronic thromboembolic disease; IPAH: idiopathic pulmonary arterial hypertension; PE: pulmonary embolism; WHO: World Health Organization; 6MWD: 6-minute walk distance; mPAP: mean pulmonary arterial pressure; PVR: pulmonary vascular resistance; WCC: white cell count; CRP: C-reactive protein; NT-proBNP: N-terminal pro-brain natriuretic peptide.